PRAX Stock Risk & Deep Value Analysis
Praxis Precision Medicines Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About PRAX Stock
We analyzed Praxis Precision Medicines Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PRAX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
PRAX Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is a regulatory setback for PRAX-118 or a significant miss in commercialization post-approval. This would lead to continued high cash burn, necessitate further dilutive financing rounds, and could cause the stock to drop 30-50% as confidence in the lead asset and platform diminishes.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
High
Red Flags
- ⚠
High cash burn rate with no immediate revenue, requiring substantial future capital.
- ⚠
Significant dependence on PRAX-118 approval and commercial success.
- ⚠
Any delay or setback in clinical trials for PRAX-562 or other pipeline assets.
Upcoming Risk Events
- 📅
PRAX-118 Complete Response Letter (CRL) from FDA (late 2026)
- 📅
Slower-than-expected commercial uptake for PRAX-118 post-launch
- 📅
Disappointing Phase 3 results or safety concerns for PRAX-562
When to Reconsider
- 🚪
Receipt of a Complete Response Letter (CRL) for PRAX-118 from the FDA.
- 🚪
Quarterly cash runway falling below 6 quarters without clear financing plans.
- 🚪
Phase 3 trial failure or unexpected safety issues for PRAX-562.
Unlock PRAX Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Praxis Precision Medicines Inc (PRAX) Do?
Sector
Healthcare
Industry
Biotechnology
Employees
116
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company's platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase 3 clinical trial for the treatment of essential tremor; Vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; Relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020 to treat KCNT1; and PRAX-050. In addition, the company develops Elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080 that targets PCDH19-related developmental epilepsy; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.
Visit Praxis Precision Medicines Inc WebsiteInvestment Thesis
Praxis is a high-growth biotech positioned to capture significant share in large, underserved CNS markets via its late-stage pipeline, particularly with PRAX-118's anticipated approval in Essential Tremor. Successful commercialization of PRAX-118 and progression of PRAX-562 will validate its platform, generate substantial revenue, and drive market leadership, justifying a multi-bagger return over 3-5 years.
Is PRAX Stock Undervalued?
Unlock the full AI analysis for PRAX
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
PRAX Price Targets & Strategy
12-Month Target
$415.00
Bull Case
$550.00
Bear Case
$250.00
Valuation Basis
Based on 8x projected FY2027 peak sales of PRAX-118 ($1.3B) and pipeline valuation, discounted by probability of success.
Entry Strategy
Dollar-cost average between $300-$320, consolidating near the 50-day SMA if it dips.
Exit Strategy
Take 30% profit at $450, 70% at $550. Stop loss at $280 if PRAX-118 regulatory news is negative or sales disappoint.
Portfolio Allocation
7-10% for aggressive risk tolerance.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Does PRAX Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat will persist and strengthen with successful regulatory approvals, market adoption, and further pipeline development, establishing Praxis as a leader in CNS disorders. Patent protection is critical for durability.
Moat Erosion Risks
- •Expiry or invalidation of key patents.
- •Development of superior competing therapies by larger pharmaceutical companies.
- •Clinical failures of pipeline candidates.
PRAX Competitive Moat Analysis
Sign up to see competitive advantages
PRAX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bullish, driven by anticipation of PRAX-118 approval and overall pipeline strength.
Institutional Sentiment
Positive, with recent analyst upgrades and increased institutional holdings post-NDA submission for PRAX-118.
Insider Activity (Form 4)
CFO sold 5,000 shares ($1.6M) on 2026-03-15 after a significant price run-up. Board Member bought 2,000 shares ($640K) on 2026-02-01.
Options Flow
Slightly bullish bias, with increased call option activity on near-term expiry dates, indicating anticipation of positive regulatory news.
Earnings Intelligence
Next Earnings
Estimated mid-May 2026
Surprise Probability
Medium
Historical Earnings Pattern
Stock price tends to react significantly to clinical and regulatory updates rather than purely financial results. Positive news drives rallies, while setbacks lead to sharp declines.
Key Metrics to Watch
Competitive Position
Top Competitor
Neurocrine Biosciences (`NBIX`)
Market Share Trend
Not yet commercialized, but poised to gain significant market share in underserved Essential Tremor and epilepsy markets with successful launches.
Valuation vs Peers
Trading at a premium to some pre-revenue biotechs due to late-stage pipeline, but a discount to commercial-stage CNS peers on a P/S basis (pre-revenue) given its potential.
Competitive Advantages
- •Proprietary small molecule compounds with novel mechanisms of action.
- •Strong intellectual property protection for lead assets.
- •Addressing large CNS markets with high unmet medical needs.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive PRAX Stock Higher?
Near-Term (0-6 months)
- •PRAX-118 NDA acceptance and PDUFA date assignment (Q2 2026)
- •Q1 2026 Earnings Report (Estimated mid-May 2026)
- •Updates on PRAX-562 Phase 3 patient enrollment/progress (Q2/Q3 2026)
Medium-Term (6-18 months)
- •PRAX-118 FDA approval (Late 2026 / Early 2027)
- •Initial commercial launch and sales data for PRAX-118 (Q1/Q2 2027)
- •Potential strategic partnerships for ex-US commercialization (H2 2026 / 2027)
Long-Term (18+ months)
- •PRAX-118 peak sales achievement and market leadership in Essential Tremor (2028-2030)
- •PRAX-562 regulatory approval and commercialization in severe epilepsies (2028+)
- •Further pipeline expansion and clinical development of earlier-stage assets
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for PRAX?
- ✓
Acceleration in PRAX-118 sales trajectory post-launch
- ✓
Positive clinical readouts for PRAX-562 and other pipeline assets
- ✓
Any new strategic partnerships or licensing deals
Bull Case Analysis
See what could go right with Premium
Competing with PRAX
See how Praxis Precision Medicines Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Praxis Precision Medicines Inc PRAX | — | 7.9 | — | — | — | — | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Praxis Precision Medicines Inc (PRAX)?
As of April 1, 2026, Praxis Precision Medicines Inc has a DVR Score of 7.9 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What ticker symbol does Praxis Precision Medicines Inc use?
PRAX is the ticker symbol for Praxis Precision Medicines Inc. The company trades on the NMS.
What is the risk level for PRAX stock?
Our analysis rates Praxis Precision Medicines Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the PRAX DVR analysis updated?
Our AI-powered analysis of Praxis Precision Medicines Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 1, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PRAX (Praxis Precision Medicines Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.